@article{MTMT:34827495, title = {A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association ( HFA ) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function}, url = {https://m2.mtmt.hu/api/publication/34827495}, author = {Ameri, Pietro and Mercurio, Valentina and Pollesello, Piero and Anker, Markus S. and Backs, Johannes and Bayes‐Genis, Antoni and Borlaug, Barry A. and Burkhoff, Daniel and Caravita, Sergio and Chan, Stephen Y. and de Man, Frances and Giannakoulas, George and González, Aránzazu and Guazzi, Marco and Hassoun, Paul M. and Hemnes, Anna R. and Maack, Cristoph and Madden, Brendan and Melenovsky, Vojtech and Müller, Oliver J. and Papp, Zoltán and Pullamsetti, Soni Savai and Rainer, Peter P. and Redfield, Margaret M. and Rich, Stuart and Schiattarella, Gabriele G. and Skaara, Hall and Stellos, Kostantinos and Tedford, Ryan J. and Thum, Thomas and Vachiery, Jean Luc and van der Meer, Peter and Van Linthout, Sophie and Pruszczyk, Piotr and Seferovic, Petar and Coats, Andrew J.S. and Metra, Marco and Rosano, Giuseppe and Rosenkranz, Stephan and Tocchetti, Carlo Gabriele}, doi = {10.1002/ejhf.3236}, journal-iso = {EUR J HEART FAIL}, journal = {EUROPEAN JOURNAL OF HEART FAILURE}, unique-id = {34827495}, issn = {1388-9842}, abstract = {Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH‐LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH‐LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH‐LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre‐clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early‐stage development of candidate therapies for PH‐LHF.}, year = {2024}, eissn = {1879-0844} } @article{MTMT:34820678, title = {Metabolic Syndrome and Biotherapeutic Activity of Dairy (Cow and Buffalo) Milk Proteins and Peptides: Fast Food-Induced Obesity Perspective—A Narrative Review}, url = {https://m2.mtmt.hu/api/publication/34820678}, author = {Abdisa, Kenbon Beyene and Némethné Szerdahelyi, Emőke and Molnár, Máté András and Friedrich, László and Lakner, Zoltán and Koris, András and Tóth, Attila and Nath, Arijit}, doi = {10.3390/biom14040478}, journal-iso = {BIOMOLECULES}, journal = {BIOMOLECULES}, volume = {14}, unique-id = {34820678}, issn = {2218-273X}, abstract = {Metabolic syndrome (MS) is defined by the outcome of interconnected metabolic factors that directly increase the prevalence of obesity and other metabolic diseases. Currently, obesity is considered one of the most relevant topics of discussion because an epidemic heave of the incidence of obesity in both developing and underdeveloped countries has been reached. According to the World Obesity Atlas 2023 report, 38% of the world population are presently either obese or overweight. One of the causes of obesity is an imbalance of energy intake and energy expenditure, where nutritional imbalance due to consumption of high-calorie fast foods play a pivotal role. The dynamic interactions among different risk factors of obesity are highly complex; however, the underpinnings of hyperglycemia and dyslipidemia for obesity incidence are recognized. Fast foods, primarily composed of soluble carbohydrates, non-nutritive artificial sweeteners, saturated fats, and complexes of macronutrients (protein-carbohydrate, starch-lipid, starch-lipid-protein) provide high metabolic calories. Several experimental studies have pointed out that dairy proteins and peptides may modulate the activities of risk factors of obesity. To justify the results precisely, peptides from dairy milk proteins were synthesized under in vitro conditions and their contributions to biomarkers of obesity were assessed. Comprehensive information about the impact of proteins and peptides from dairy milks on fast food-induced obesity is presented in this narrative review article.}, year = {2024}, eissn = {2218-273X}, pages = {478}, orcid-numbers = {Abdisa, Kenbon Beyene/0000-0002-4641-2823; Némethné Szerdahelyi, Emőke/0000-0003-2419-5802; Koris, András/0000-0002-2284-8139} } @article{MTMT:34719971, title = {Case report: Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss}, url = {https://m2.mtmt.hu/api/publication/34719971}, author = {Tóth, Eszter Lilla and Orbán-Kálmándi, Rita Angéla and Bagoly, Zsuzsa and Lóczi, Linda and Deli, Tamás and Török, Olga and Molnár, Sarolta and Baráth, Sándor and Singh, Parvind and Hevessy Zsuzsanna, Dóra and Katona, Éva and Fagyas, Miklós and Szabó, Attila Ádám and Molnár, Szabolcs and Krasznai, Zoárd Tibor}, doi = {10.3389/fimmu.2024.1329236}, journal-iso = {FRONT IMMUNOL}, journal = {FRONTIERS IN IMMUNOLOGY}, volume = {15}, unique-id = {34719971}, issn = {1664-3224}, year = {2024}, eissn = {1664-3224}, pages = {1}, orcid-numbers = {Orbán-Kálmándi, Rita Angéla/0000-0002-2155-8279; Bagoly, Zsuzsa/0000-0001-5314-5607; Katona, Éva/0000-0003-3476-794X} } @article{MTMT:34689913, title = {Editors' highlight picks from 2023 in ESC heart failure}, url = {https://m2.mtmt.hu/api/publication/34689913}, author = {Bäck, Magnus and von Haehling, Stephan and Papp, Zoltán and Piepoli, Massimo F.}, doi = {10.1002/ehf2.14727}, journal-iso = {ESC HEART FAIL}, journal = {ESC HEART FAILURE}, unique-id = {34689913}, issn = {2055-5822}, abstract = {Heart failure is a devastating syndrome affecting an increasingly high number of patients worldwide. Its aetiology and pathogenesis are complex with the involvement of factors ranging from the genetic material through valvular dysfunctions to numerous organs beyond the entire cardiovascular system. Based on continuous efforts of the heart failure scientific community we have witnessed major advances in many related disciplines during the last year. For example, epidemiological aspects—paving the road for improved risk prevention—have been thoroughly analysed for various geographical regions. Additionally, evidence‐based approaches now allow the introduction of novel guideline recommended medical therapies (i.e. sodium‐glucose transporter 2 inhibitors, and iron supplementation) while basic and translational research aim to explore additional molecular targets for future heart failure diagnostics and medications. All above aspects are addressed in this article, where a selection of articles published in the ESC Heart Failure journal in 2023 are highlighted. The editors are confident that the scientific contributions of ESC Heart Failure effectively served a highly relevant area of cardiovascular research last year.}, year = {2024}, eissn = {2055-5822} } @article{MTMT:34528941, title = {Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection}, url = {https://m2.mtmt.hu/api/publication/34528941}, author = {Sütő, Renáta and Pócsi, Marianna and Fagyas, Miklós and Kalina, Edit and Fejes, Zsolt and Szentkereszty, Zoltán and Kappelmayer, János and Nagy, Béla}, doi = {10.3390/microorganisms12010229}, journal-iso = {MICROORGANISMS}, journal = {MICROORGANISMS}, volume = {12}, unique-id = {34528941}, issn = {2076-2607}, abstract = {Severe SARS-CoV-2 elicits a hyper-inflammatory response that results in intravascular inflammation with endothelial injury, which contributes to increased mortality in COVID-19. To predict the outcome of severe SARS-CoV-2 infection, we analyzed the baseline level of different biomarkers of vascular disorders in COVID-19 subjects upon intensive care unit (ICU) admission and prior to any vaccination. A total of 70 severe COVID-19 patients (37 survivors and 33 non-survivors) were included with 16 age- and sex-matched controls. Vascular dysfunction was monitored via soluble VCAM-1, E-selectin, ACE2 and Lp-PLA2, while abnormal platelet activation was evaluated by soluble P-selectin and CD40L in parallel. These results were correlated with routine laboratory parameters and disease outcomes. Among these parameters, VCAM-1 and ACE2 showed significantly higher serum levels in COVID-19 patients with early death vs. convalescent subjects. VCAM-1 was significantly correlated with the Horowitz index (r = 0.3115) and IL-6 (r = 0.4599), while ACE2 was related to E-selectin (r = 0.4143) and CD40L (r = 0.2948). Lp-PLA2 was altered in none of these COVID-19 subcohorts and showed no relationship with the other parameters. Finally, the pre-treatment level of VCAM-1 (≥1420 ng/mL) and ACE2 activity (≥45.2 μU/mL) predicted a larger risk for mortality (Log-Rank p = 0.0031 and p = 0.0117, respectively). Vascular dysfunction with endothelial cell activation is linked to lethal COVID-19, and highly elevated soluble VCAM-1 and ACE2 at admission to ICU may predict unfavorable outcomes.}, year = {2024}, eissn = {2076-2607}, pages = {229}, orcid-numbers = {Fagyas, Miklós/0000-0003-3262-884X; Fejes, Zsolt/0000-0002-1387-2970} } @article{MTMT:34496858, title = {Get reliable laboratory findings – how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis?}, url = {https://m2.mtmt.hu/api/publication/34496858}, author = {Szabó, Attila Ádám and Enyedi, Enikő Edit and Altorjay, István and Hajnal, Péter and Pintér, Tamás Bence and Mányiné Siket, Ivetta and Váradi, Csongor and Bányai, Emese and Tóth, Attila and Papp, Zoltán and Fagyas, Miklós}, doi = {10.1515/cclm-2023-1288}, journal-iso = {CLIN CHEM LAB MED}, journal = {CLINICAL CHEMISTRY AND LABORATORY MEDICINE}, unique-id = {34496858}, issn = {1434-6621}, abstract = {Objectives Serum angiotensin-converting enzyme (ACE) is the only biomarker routinely used in the laboratory diagnostics of sarcoidosis, and ACE inhibitor (ACEi) drugs are among the most prescribed drugs worldwide. Taking ACEi can mislead medical teams by lowering ACE activity, delaying diagnosis and giving a false impression of disease activity of sarcoidosis. We aimed to develop a simple method to detect the presence of ACEi drugs in samples, to investigate the ACEi medication-caused interference and consequences in a retrospective study. Methods ACE activity and the level of ACE inhibition were determined for 1823 patients with suspected sarcoidosis. These values were compared with the therapeutic information at the first and follow-up visits. Results A total of 302 patients had biochemical evidence of an ACEi drug effect during diagnostic ACE activity testing. In their case, ACE activity was significantly lower (median(IQR): 4.41 U/L(2.93–6.72)) than in patients not taking ACEi (11.32 U/L(8.79–13.92), p<0.01). In 62 sarcoidosis patients, the ACEi reduced ACE activity to the reference range or below. Only in 40 % of the cases was the medication list recorded in the outpatient chart and only in 3 cases was low ACE activity associated with ACEi use. 67 % of the repeated ACE activity measurements were also performed during ACEi therapy. Conclusions Our study revealed that the use of ACEi is common in patients with suspected sarcoidosis. The ACE activity lowering effect of ACEi drugs may escape the attention of medical teams which can lead to diagnostic errors and unnecessary tests. Nevertheless, these pitfalls can be avoided by using a method suggested by our team.}, year = {2024}, eissn = {1437-4331}, orcid-numbers = {Váradi, Csongor/0000-0001-7332-1524; Fagyas, Miklós/0000-0003-3262-884X} } @article{MTMT:34148390, title = {Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients}, url = {https://m2.mtmt.hu/api/publication/34148390}, author = {Tóth, Emese and Fagyas, Miklós and Nagy, Béla and Siket, Ivetta Mányiné and Szőke, Blanka and Mártha, Lilla and Mahdi, Mohamed and Erdősi, Gábor and Pólik, Zsófia and Kappelmayer, János and Papp, Zoltán and Borbély, Attila and Szabó, Tamás and Balla, József and Balla, György and Bácsi, Attila and Szekanecz, Zoltán and Bay, Péter and Tóth, Attila}, doi = {10.1007/s11357-023-00887-2}, journal-iso = {GEROSCIENCE}, journal = {GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)}, volume = {46}, unique-id = {34148390}, issn = {2509-2715}, abstract = {Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment.}, year = {2024}, eissn = {2509-2723}, pages = {1561-1574} } @article{MTMT:34768455, title = {Repetitive LevosimenDan infusionS for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial}, url = {https://m2.mtmt.hu/api/publication/34768455}, author = {Poelzl, G. and Altenberger, J. and Comin-Colet, J. and Delgado, J. F. and Fedele, F. and Carcia-Gonzales, M. J. and Gustafsson, F. and Masip, J. and Papp, Zoltán and Stoerk, S. and Ulmer, H. and Maier, S. and Vrtovec, B. and Wikstroem, G. and Zima, E. and Bauer, A.}, journal-iso = {WIEN KLIN WOCHENSCHR}, journal = {WIENER KLINISCHE WOCHENSCHRIFT: MIDDLE EUROPEAN JOURNAL OF MEDICINE}, volume = {135}, unique-id = {34768455}, issn = {0043-5325}, year = {2023}, eissn = {1613-7671}, pages = {S345-S346} } @article{MTMT:34722686, title = {Repetitive LevosimenDan infusions fOR patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial}, url = {https://m2.mtmt.hu/api/publication/34722686}, author = {Polzl, G. and Altenberger, J. and Comin-Colet, J. and Delgado, J. and Fedele, F. and Garcia-Gonzales, M. J. and Gustafsson, F. and Masip, J. and Papp, Zoltán and Stoerk, S. and Ulmer, H. and Vrtovec, B. and Wikstrom, G. and Zima, E. and Bauer, A.}, journal-iso = {EUR HEART J}, journal = {EUROPEAN HEART JOURNAL}, volume = {44}, unique-id = {34722686}, issn = {0195-668X}, year = {2023}, eissn = {1522-9645}, pages = {-} } @article{MTMT:34689842, title = {Myocardial work index and myofilament calcium sensitivity: possible hand in hand markers of contractility in aortic valve stenosis patients - a translational study}, url = {https://m2.mtmt.hu/api/publication/34689842}, author = {Ladanyi, Z. and Ruppert, M. and Fábián, Alexandra and Ujvari, A. and Bódi, Beáta and Papp, Zoltán and Radovits, T. and Sayour, A. A. and Molnar, L. and Straub, E. and Nagy, A. and Kovacs, A. and Lakatos, B. K. and Merkely, B.}, doi = {10.1093/eurheartj/ehad655.011}, journal-iso = {EUR HEART J}, journal = {EUROPEAN HEART JOURNAL}, volume = {44}, unique-id = {34689842}, issn = {0195-668X}, year = {2023}, eissn = {1522-9645}, orcid-numbers = {Fábián, Alexandra/0000-0002-8449-0638} }